由生成式AI驱动的临床阶段生物科技公司英矽智能宣布,研发团队采用自有药物研发和科学研究AI平台Pharma.AI,成功开发出一系列强效、高选择性HPK1抑制剂候选分子。 (IMAGE) InSilico Medicine Caption 研究结果先后以同行评议论文形式发表在European Journal of Medicinal Chemistry、ACS Medicinal Chemistry Letters和Journal of Medicinal Chemistry,持续对候选药物进行成药性质优化。 Credit 英矽智能 Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.